Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentric Randomized Double-Blind Phase 3 Trial Evaluating the Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Active Hidradenitis Suppurativa Patients Versus Tetracycline Derivative

Next Previous
Trial Profile

A Multicentric Randomized Double-Blind Phase 3 Trial Evaluating the Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Active Hidradenitis Suppurativa Patients Versus Tetracycline Derivative

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ceftriaxone (Primary) ; Metronidazole (Primary) ; Moxifloxacin (Primary) ; Rifampicin (Primary) ; Lymecycline
  • Indications Hidradenitis suppurativa
  • Focus Therapeutic Use
  • Acronyms ABCESS2

Most Recent Events

  • 09 Jul 2025 Planned End Date changed from 15 Sep 2026 to 27 Feb 2028.
  • 09 Jul 2025 Planned primary completion date changed from 15 Dec 2025 to 28 Feb 2027.
  • 09 Jul 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top